APPROVAL OF ONCOLOGY DRUGS AT WORLD-WIDE LEVEL: AN INDEPENDENT OR LINKED MARKET?

被引：0
|
作者：
Aissaoui, A. [1 ]
Bin Sawad, A. [2 ]
机构：
[1] Univ Paris 09, PSL, Paris, France
[2] MCPHS Univ, Boston, MA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
Approval; EMA; FDA; Health Canada; Oncology; Orphan; Swissmedic; TGA;
D O I：
10.1016/j.jval.2016.03.1506
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN173
引用
收藏
页码：A164 / A164
页数：1
相关论文
共 34 条
  • [31] Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
    Lau, Catherine
    Dranitsaris, George
    CURRENT ONCOLOGY, 2022, 29 (11) : 8031 - 8042
  • [32] Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau, Catherine Y.
    Rawson, Nigel S. B.
    CURRENT ONCOLOGY, 2024, 31 (09) : 5599 - 5607
  • [33] ONCOLOGY DRUGS GAINING FDA APPROVAL FOR LOW SURVIVAL INDICATIONS AND ENTERING FIRST TO MARKET ARE ASSOCIATED WITH LESS MATURE CLINICAL DATA COMPARED TO LATER ENTRANTS
    Shohet, S.
    Schmetz, A.
    Ansart, S.
    Feuilly, M.
    Shah, S.
    Hollywood, A.
    Laughlin, W.
    VALUE IN HEALTH, 2019, 22 : S58 - S59
  • [34] A methodology for evaluating the relative pollution level of metal pollution in surface sediments of rivers based on the statistical results of relevant literatures covering world-wide rivers
    Ru, Xuan
    Guan, Xianghong
    Liao, Jianbo
    Wei, Cong
    Wu, Haizhen
    Wei, Chaohai
    JOURNAL OF HAZARDOUS MATERIALS, 2024, 465
1234